Eli Lilly (LLY) Non-Current Deferred Tax Liability (2018 - 2022)
Eli Lilly (LLY) has disclosed Non-Current Deferred Tax Liability for 11 consecutive years, with $87.3 million as the latest value for Q4 2022.
- For the quarter ending Q4 2022, Non-Current Deferred Tax Liability fell 94.96% year-over-year to $87.3 million, compared with a TTM value of $87.3 million through Dec 2022, down 94.96%, and an annual FY2022 reading of $87.3 million, down 94.96% over the prior year.
- Non-Current Deferred Tax Liability was $87.3 million for Q4 2022 at Eli Lilly, down from $171.9 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $5.1 billion in Q4 2020 and bottomed at $87.3 million in Q4 2022.
- Average Non-Current Deferred Tax Liability over 5 years is $2.0 billion, with a median of $2.0 billion recorded in 2020.
- The sharpest move saw Non-Current Deferred Tax Liability skyrocketed 250.8% in 2019, then crashed 94.96% in 2022.
- Year by year, Non-Current Deferred Tax Liability stood at $1.3 billion in 2018, then surged by 250.8% to $4.6 billion in 2019, then rose by 10.13% to $5.1 billion in 2020, then plummeted by 65.81% to $1.7 billion in 2021, then plummeted by 94.96% to $87.3 million in 2022.
- Business Quant data shows Non-Current Deferred Tax Liability for LLY at $87.3 million in Q4 2022, $171.9 million in Q3 2022, and $862.5 million in Q2 2022.